Efficacy of Olezarsen in Severe Hypertriglyceridemia and Acute Pancreatitis Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - PubMed
3 hours ago
- #Pancreatitis
- #Olezarsen
- #Hypertriglyceridemia
- Olezarsen significantly reduces triglyceride (TG) levels in severe hypertriglyceridemia (SHTG), especially in non-familial chylomicronemia syndrome (non-FCS) populations.
- The drug also lowers apolipoprotein C-III levels, non-HDL cholesterol, and remnant cholesterol, though it increases LDL levels.
- Olezarsen reduces the risk of acute pancreatitis compared to placebo, with a notable risk ratio (RR = 0.14).
- No significant adverse events were observed between the olezarsen and placebo groups.
- Long-term safety and efficacy of olezarsen in SHTG patients require further exploration in future trials.